Quiz Ref ID Statin therapy significantly reduces cardiovascular events among individuals with and without a history of diabetes mellitus compared with placebo.
1,2 Intensive-dose statin therapy has also been shown to further reduce cardiovascular events compared with moderate-dose statin therapy.
1,3 A recent meta-analysis of 13 randomized placebo and standard care controlled trials involving 91 140 individuals reported that among patients treated with statins, the risk of developing diabetes was 9% higher (95% confidence interval [CI], 2%-17%) over a 4-year period compared with patients randomized to placebo or standard care.
4 Recently, findings of 3 large end-point trials comparing intensive- to moderate-dose statin therapy have suggested an excess risk of incident diabetes among those treated with intensive statin regimens.
5,6 However, 2 of these trials used nonstandard diagnostic criteria previously used to define incident diabetes.
7 Additionally, published data from a fourth large clinical trial suggested the possibility of a deterioration in glucose control in patients receiving intensive statin therapy,
8 and a recent report of 220 patients with hypercholesterolemia treated with placebo or different doses of atorvastatin and followed up for only 2 months found that those receiving the highest dose developed greater insulin resistance, higher insulin levels, and higher hemoglobin A
1c levels compared with those receiving the lowest dose or placebo,
9 suggesting a potential dose effect. Although no significant relationship was observed between the extent of decreasing low-density lipoprotein (LDL) cholesterol values and new-onset diabetes in the meta-analysis of placebo and standard care controlled trials,
4 most of those trials used modest-intensity statins and trial populations also differed greatly, which may have obscured any meaningful association.